General Biologicals Corp. Statistics
General Biologicals Corp. (4117) Stock Statistics & Valuation Metrics
Total Valuation
General Biologicals Corp. has a market cap or net worth of TWD 616.17M. The enterprise value is ―.
- Market Cap
- TWD 616.17M
- Enterprise Value
- ―
Share Statistics
General Biologicals Corp. has 70,824,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 70,824,370
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
General Biologicals Corp.’s return on equity (ROE) is 0.54 and return on invested capital (ROIC) is -4.37%.
- Return on Equity (ROE)
- 0.54
- Return on Assets (ROA)
- 0.10
- Return on Invested Capital (ROIC)
- -4.37%
- Return on Capital Employed (ROCE)
- -0.05
- Revenue Per Employee
- 1.08M
- Profits Per Employee
- 2.33M
- Employee Count
- 200
- Asset Turnover
- 0.04
- Inventory Turnover
- 2.65
Valuation Ratios
The current PE Ratio of General Biologicals Corp. is 0.97. General Biologicals Corp.’s PEG ratio is 0.00.
- PE Ratio
- 0.97
- PS Ratio
- 2.32
- PB Ratio
- 0.76
- Price to FCF
- -7.31
- Price to Operating Cash Flow
- -7.80
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, General Biologicals Corp. had revenue of 215.74M and earned 465.84M in profits. Earnings per share was 7.79.
- Revenue
- 215.74M
- Gross Profit
- 59.62M
- Operating Income
- -218.37M
- Pretax Income
- 505.51M
- Net Income
- 465.84M
- EBITDA
- 604.30M
- Earnings Per Share (EPS)
- 7.79
Cash Flow
In the last 12 months, operating cash flow was -77.27M and capital expenditures -5.27M, giving a free cash flow of -82.54M billion.
- Operating Cash Flow
- -77.27M
- Free Cash Flow
- -82.54M
- Free Cash Flow per Share
- -1.17
Dividends & Yields
General Biologicals Corp. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.39%
- Earnings Yield
- 90.56%
Stock Price Statistics
- Beta
- -0.37
- 52-Week Price Change
- -32.30%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 58.82
- Average Volume (3m)
- 160.77K
Financial Position
General Biologicals Corp. as a current ratio of 2.00, with Debt / Equity ratio of 286.70%
- Current Ratio
- 2.00
- Quick Ratio
- 1.85
- Debt to Market Cap
- 2.71
- Net Debt to EBITDA
- 3.73
- Interest Coverage Ratio
- -11.07
Taxes
In the past 12 months, General Biologicals Corp. has paid 40.67M in taxes.
- Income Tax
- 40.67M
- Effective Tax Rate
- 0.08
Enterprise Valuation
General Biologicals Corp. EV to EBITDA ratio is 4.53, with an EV/FCF ratio of -35.06.
- EV to Sales
- 11.12
- EV to EBITDA
- 4.53
- EV to Free Cash Flow
- -35.06
- EV to Operating Cash Flow
- -37.45
Balance Sheet
General Biologicals Corp. has TWD 606.76M in cash and marketable securities with TWD 2.53B in debt, giving a net cash position of -TWD 1.92B billion.
- Cash & Marketable Securities
- TWD 606.76M
- Total Debt
- TWD 2.53B
- Net Cash
- -TWD 1.92B
- Net Cash Per Share
- -TWD 27.17
- Tangible Book Value Per Share
- TWD 10.68
Margins
Gross margin is 34.07%, with operating margin of -65.68%, and net profit margin of 199.43%.
- Gross Margin
- 34.07%
- Operating Margin
- -65.68%
- Pretax Margin
- 216.12%
- Net Profit Margin
- 199.43%
- EBITDA Margin
- 245.39%
- EBIT Margin
- 216.82%
Analyst Forecast
The average price target for General Biologicals Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 3.52%
- EPS Growth Forecast
- ―
